Home | CARsgen

Making
Cancer Curable

Our mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

About CARsgen^®

We focus on innovative CAR T-cell therapies

We are biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases.

About CARsgen<sup>®</sup>

Pipeline

Pipeline

Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

We have built an integrated cell therapy platform

<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR^®

Allogeneic CAR-T platform

<p>CycloCAR<sup>®</sup></p>

CycloCAR^®

Cytokine and Chemokine Loaded CAR

<p>LADAR<sup>®</sup></p>

LADAR^®

Local Action Driven by Artificial Receptor

News Center

CARsgen Therapeutics Announces 2025 Interim Results

ESMO Preview | CARsgen to Present Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

CARsgen Therapeutics Submits New Drug Application for Satri-cel to China’s NMPA

CARsgen Presents Results of GPRC5D CAR-T CT071 at EHA 2025